New psoriasis pill effective, safe

June 2008
Cortlandt Forum;Jun2008, Vol. 21 Issue 6, p10
The article reports that a new type of calcineurin inhibitor showing strong promise in a clinical trial could prove to be one of the safest and most effective therapies for plaque psoriasis. In a study of people aged 18 to 65 years with plaque psoriasis, oral ISA247 reduced the psoriatic area and severity by 75% in more subjects than did placebo. ISA247 appears to be less nephrotoxic and to cause less hypertension and hyperlipidemia than cyclosporine.


Related Articles

  • Gabapentin and nortriptyline combined was better than either drug alone for relief of neuropathic pain. Hughes, James // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p5 

    The article focuses on a medical research related to effectiveness of combined gabapentin and nortriptyline in comparison to alone drug for neuropathic pain. In a clinical trial around 56 patients with neuropathy is being observed and treated with combined drugs. It concluded that gabapentin and...

  • Withholding intravenous drugs did not improve survival to hospital discharge in out-of-hospital cardiac arrest. Stiell, Ian G. // ACP Journal Club;3/16/2010, Vol. 152 Issue 3, p7 

    The article offers information on a medical research related to intravenous drugs. It explores the effectiveness of withholding intravenous (IV) drugs in improvement of patient's health with out-of-hospital cardiac arrest. It concludes in a clinical trial that withholding intravenous drugs did...

  • A tutorial on pilot studies: the what, why and how. Thabane, Lehana; Jinhui Ma; Rong Chu; Ji Cheng; Ismaila, Afisi; Rios, Lorena P; Robson, Reid; Thabane, Marroon; Giangregorio, Lora; Goldsmith, Charles H // BMC Medical Research Methodology;2010, Vol. 10, p1 

    Pilot studies for phase III trials - which are comparative randomized trials designed to provide preliminary evidence on the clinical efficacy of a drug or intervention - are routinely performed in many clinical areas. Also commonly know as "feasibility" or "vanguard" studies, they are designed...

  • Promising Alzheimer's Drug Fails.  // MondayMorning;3/8/2010, Vol. 18 Issue 9, p3 

    The article reports that the drug, dimebon, for treating Alzheimer's disease, failed in the initial stage of its clinical trial. It informs that dimebon showed no effect after six months in treating Alzheimer's disease. Earlier trials were successful and dimebon worked really good and showed...

  • Double-Blind Active-Control Trials: Beware the Comparator You Keep. DiNubile, Mark J. // Clinical Infectious Diseases;10/15/2008, Vol. 47 Issue 8, p1064 

    The indirect impact of the known comparator drug in double-blind comparative clinical trials of novel agents is under appreciated, despite its potentially pernicious effects. This hypothesis-generating analysis illustrates potential spillover effects of a comparator (amphotericin) in the...

  • Operation Adaptive. Blake-Michaels, Molly // Applied Clinical Trials;Oct2009, Vol. 18 Issue 10, p52 

    The article reports on how the use of adaptive design could improve the overall effectiveness of a clinical trial. It notes that overall timeline may be compressed by using adaptive trials because of the higher information value and it can lower the development cost because it avoids additional...

  • Compromising the Medical Literature: The Hidden Influence of Industry-Biased Articles. FUGH-BERMAN, ADRIANE; SIWEK, JAY // American Family Physician;9/1/2011, Vol. 84 Issue 5, p489 

    This article comments on the influence of industry-biased articles published in medical journals in the U.S. It warns readers about clinical studies written for marketing rather than scientific purposes. It cautions readers about the efficacy and safety of drugs studied. In addition, the article...

  • Surrogate End Points and FDA Approval. Psaty, Bruce M.; Lumley, Thomas // JAMA: Journal of the American Medical Association;3/26/2008, Vol. 299 Issue 12, p1474 

    The authors reflect on the U.S. Food and Drug Administration's use of surrogate end points in evaluating the safety and effectiveness of drugs. They suggest that the advantage of using surrogate end points is the ability to evaluate drugs more effectively and in smaller clinical trials. They...

  • Sucampo Presents Data for AMITIZA(r) in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C).  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article offers information on the results of phase three clinical studies conducted by Sucampo Pharmaceuticals Inc. to demonstrate the efficacy of the drug, Amitiza in treatment of irritable bowel syndrome with constipation. The results related with the study were presented at Digestive...

  • New drug effective in the treatment of plaque psoriasis.  // Nursing Standard;6/4/2008, Vol. 22 Issue 39, p16 

    The article reports that ISA247, an alternative to ciclosporin, is safe and effective in the treatment of moderate to severe plaque psoriasis. ISA247 differs from ciclosporin with the result that its metabolites are excreted faster and there is a lower drug and metabolite load. Researchers in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics